Related Experiment Video
Updated: Jun 13, 2025

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Methicillin-Resistant Staphylococcus aureus has Phenotypic Variation in mecA Expression that Alters Antibiotic
Dongzhu Ma1, Rekha Arya1, Beth Ann Knapick1
1Arthritis and Arthroplasty Design Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract:
Methicillin resistant Staphylococcus aureus (MRSA) sepsis has a high rate of morbidity and mortality. Multiple clinical studies have demonstrated improved outcomes when MRSA sepsis is treated with dual antibiotic therapy that includes a β-lactam antibiotic such as cefazolin. This is a paradox as MRSA should be inherently resistant to this class of antibiotics. We report a serendipitous observation revealed a phenotype where MRSA became sensitive to cefazolin when cultured in a physiologic relevant media of fetal bovine serum as well as in synovial fluid. This could be observed across multiple clinical isolates. Expected resistance was maintained when cultured in Muller Hinton Broth (MHB). MRSA β-lactam antibiotic resistance is mediated by PBP2a, a penicillin-binding protein encoded by mecA. We hypothesized that this phenotype of antibiotic sensitivity in physiologic medium was based, in part, on levels of PBP2a expression and post-translational modifications of peptidoglycan wall teichoic acid (WTA). We therefore conducted quantitative RT-PCR analysis and Western blotting which demonstrated limited mecA expression in the mRNA level and limited PBP2a protein level when cultured in FBS or synovial fluid as compared to the clinical microbiology standard MHB, respectively. Whole genome sequencing of loss of function mutants generated through serial passaging in FBS revealed that the clp family of proteins and rpo genes were involved in β-lactam resistance. Cell wall peptidoglycan analysis suggested that WTA glycosylation was altered between β-lactam resistant and sensitive MRSA phenotypes. Together, this suggests pathways for clpP, rpoB, and WTA glycosylation can be new potential targets for MRSA treatment.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) can become sensitive to beta-lactam antibiotics like cefazolin in physiological environments, challenging resistance assumptions. This discovery offers new therapeutic targets for treating dangerous MRSA infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) sepsis presents significant morbidity and mortality.
- Clinical studies suggest dual antibiotic therapy, including beta-lactams, improves MRSA sepsis outcomes, despite MRSA's inherent resistance.
- This study investigates the paradoxical observation of MRSA sensitivity to beta-lactams in specific physiological conditions.
Purpose of the Study:
- To explore the phenotypic variation in MRSA's mecA expression and PBP2a protein levels.
- To investigate the role of environmental conditions in altering MRSA's beta-lactam antibiotic sensitivity.
- To identify novel therapeutic targets for combating multidrug-resistant bacteria.
Main Methods:
- Quantitative RT-PCR and Western blotting to assess mecA expression and PBP2a levels.
- Culturing MRSA in physiological media (fetal bovine serum, synovial fluid) versus standard media (MHB).
- Whole genome sequencing of MRSA mutants and cell wall peptidoglycan analysis.
Main Results:
- MRSA exhibited reduced mecA expression and PBP2a protein levels in physiological media compared to MHB.
- Phenotypic variation in beta-lactam sensitivity was observed across clinical MRSA isolates.
- Genes including clp family proteins and rpo genes, along with WTA glycosylation, were implicated in altered beta-lactam resistance.
Conclusions:
- Environmental conditions significantly influence MRSA's phenotypic expression of antibiotic resistance.
- The study provides a potential explanation for the clinical efficacy of beta-lactams in MRSA sepsis treatment.
- Targeting pathways involving clpP, rpoB, and WTA glycosylation presents promising strategies for new MRSA therapies.

